BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Syrian army says recent drone attacks targeted its bases near Iraq, most shot down - 2Burkina Faso forces killed twice as many civilians as jihadists, rights group says
- 3I'm an 83-year-old yoga instructor. I'm not your typical grandma — I still work to feel fulfilled and supplement my Social Security.
- 4Vote in favor of your Favored kind of craftsmanship
- 5Iran war drives global fertilizer prices up, raising food cost fears
- Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion
- NASA releases new photos of interstellar comet 3I/ATLAS
- Ever Wonder What An EV Motorcycle Water Crossing Would Be Like? Here You Go
- Venezuelans in Madrid celebrate Maduro's capture
- Ultra-Orthodox protests erupt across Israel on haredi IDF enlistment day
- Florence's Uffizi Gallery moves treasures to safety after cyberattack
- Like many holiday traditions, lighting candles and fireplaces is best done in moderation
- Israeli military says it hit dozens of military facilities in Tehran
- Monetary Strengthening: Assuming Command over Your Cash
